Edwyn
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | $11,673 | $12,784 | $15,113 | $14,813 | $10,636 |
| Gross Profit | $4,587 | $5,105 | $5,397 | $4,975 | $3,984 |
| Operating Income | $1,616 | $1,710 | -$1,943 | $390 | $14 |
| Net Income | $1,102 | $1,284 | -$2,433 | $2,656 | -$649 |
Over the five-year period examined, Baxter International’s revenue generally trended upward from 2020 (USD 11,673 million) to a peak in 2022 (USD 15,113 million), before experiencing a steep decline to USD 10,636 million in 2024. Gross profit exhibited a similar trend, growing from USD 4,587 million in 2020 to USD 5,397 million in 2022, then falling to USD 3,984 million in 2024. Particularly noteworthy is the significant year-over-year swing in operating income and net income: after registering positive operating income of USD 1,616 million and net income of USD 1,102 million in 2020, the company experienced a drastic reversal in 2022 with operating losses of USD 1,943 million and a net loss of USD 2,433 million—exceeding 200% negative swings compared to prior positive values. The recovery in operating income in 2023 (USD 390 million) and improved net income (USD 2,656 million) was short-lived, as the 2024 figures show operating income barely positive (USD 14 million) and net losses (USD -649 million), marking substantial volatility. This performance suggests that despite early growth, Baxter International’s earnings have been highly sensitive to operational or market shifts, which likely impacted margins. The reversal in 2022 may be attributed to industry-wide challenges or internal cost pressures, while the subsequent recovery and decline in later years underscore ongoing uncertainties in maintaining profitability. Overall, the company’s fluctuating performance points to a need for greater operational stability and strategic adjustments to sustain long-term financial health amidst an evolving healthcare and medical devices industry.
This analysis is for informational purposes only and does not constitute financial advice or recommendations for any investment decisions. Please consult with a qualified financial professional for personalized guidance.